Measles Vaccine: Is There a Protective Role in COVID 19 Pandemic?

• Conditions: Coronavirus (COVID-19)

• Registration Number: NCT04445610
• Lead Sponsor: Ain Shams University

Brief Summary

The following two mechanisms that explain the ability of measles vaccine to cause partial protection against COVID-19. The first is that measles vaccine may increase the ability of the immune system to fight off pathogens other than measles due to the generated bystander immunity that would enhance the overall immunity against the new coronavirus. The second is that SARS-CoV-2 is proven to have structure similarities with measles, which may cause cross-reactivity and immunity between measles vaccines and COVID-19, leading to partial protection against COVID-19 in vaccinated subjects

Detailed Description

Objectives:

1. To identify Measles IgG titre in SARS-COV2 infected patients .

2. correlate level of Measles IgG titre with the clinical severity of COVID-19 disease.

Secondary Objective To find an association of the postulated protective role of measles vaccine and SARS-COV2 infection

Criteria:

Inclusion criteria:included patients would be divided into 3 groups according to clinical severity of COVID-19 disease (mild ,moderate \& severe)

* All patients with confirmed COVID 19 confirmed by positive PCR . .

* Any age or gender.

Exclusion criteria:

- Any patient refusing to be involved in the study.

Methods:

* Informed consent will be taken from each subject

* Full clinical examination.

* Evaluation of Measles Antibody Titer:

The measles virus IgG antibody titer will be determined quantitatively by ELISA for quantitative determination of IgG class antibodies against Measles virus in human serum or plasma (citrate, heparin).

- Anonymous data will be retrieved from the admitted patients' files, such as:

* CBC, CRP, AST, ALT, ESR, Serum ferritin \& SARS CoV 2 RNA PCR swab results.

* Chest X ray and/or CT chest.

Study Timeline

• Status Verified: 2020-06
• Study First Submitted: 2020-06-23
• Study First Submitted QC: 2020-06-23
• Study First Posted: 2020-06-24
• Last Update Submitted: 2020-06-24
• Last Update Posted: 2020-06-26
• Study Start: 2020-07-01
• Primary Completion: 2020-09-01
• Study Completion: 2020-11-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• All patients with confirmed COVID 19.
• Any age or gender

Read More

Exclusion Criteria

• • Any patient refusing to be involved in the study

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Viral clearance	6 months	Achievement of two consecutive negative PCR results for COVID 19 and discharge from hospital

Trial Locations

Locations (1)

Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center; 🇪🇬 Cairo, Non-US, Egypt